| 张 龙,吴小燕,高金玉,李 群,杨国强,葛 纪,刘 赟.不同剂量阿加曲班联合丁苯酞对急性脑梗死患者效果及预后的影响因素分析[J].现代生物医学进展英文版,2024,(12):2279-2283. |
| 不同剂量阿加曲班联合丁苯酞对急性脑梗死患者效果及预后的影响因素分析 |
| Analysis of the Influence Factors on the Effect and Prognosis of Different Doses of Agatroban Combined with Butylphthalein in Patients with Acute Cerebral Infarction |
| Received:November 09, 2023 Revised:November 30, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.12.014 |
| 中文关键词: 高剂量阿加曲班 低剂量阿加曲班 丁苯酞 急性脑梗死 |
| 英文关键词: High-dose agatroban Low dose agatroban Butylphthalein Acute cerebral infarction |
| 基金项目:江苏省科技项目基础研究计划（自然科学基金）--青年基金项目（BK20210087） |
|
| Hits: 220 |
| Download times: 160 |
| 中文摘要: |
| 摘要 目的：本研究旨在探讨不同剂量阿加曲班联合丁苯酞对急性脑梗死患者效果及预后的影响因素。方法：以自2019年6月到2022年8月在我院收治的90例急诊急性脑梗死为研究对象，采用随机数字表法将其分为高剂量组（给予高剂量阿加曲班联合丁苯酞治疗）和低剂量组（给予低剂量阿加曲班联合丁苯酞治疗）各45例。对比治疗7 d后两组临床疗效及预后，分析治疗前及治疗7 d后两组神经功能[中国卒中量表（CSS）评分、神经功能（NIHSS）评分]，根据不同预后将患者分为预后良好组和预后不良组，采用单/多因素Logisitic回归分析急性脑梗死预后的影响因素。结果：（1）将两组的临床疗效纳入研究并实施组间差异性比较，结果显示，高剂量组总有效率高于低剂量组（P＜0.05）。（2）将两组的神经功能采用CSS评分、NIHSS评分评估纳入研究并实施组间差异性比较，结果显示治疗前，两组采用CSS评分、NIHSS评分比较（P＞0.05）；治疗7 d后，高剂量组采用CSS评分、NIHSS评分高于低剂量组（P＜0.05）。（3）将两组的预后采用mRS评分评估纳入研究并实施组间差异性比较，结果显示，高剂量组预后良好2.22%（1/45）高于低剂量组15.56%（7/45）（P＜0.05）。（4）预后良好组患者年龄、治疗前CSS评分及治疗前NIHSS评分与预后不良组存在差异（P＜0.05）。（5）以急性脑梗死预后为因变量，以单因素中对比有差异的指标为自变量，经多因素Logisitic回归分析急性脑梗死预后的影响因素为治疗前CSS评分及治疗前NIHSS 评分。结论：高剂量阿加曲班联合丁苯酞能够有效治疗急性脑梗死患者，而急性脑梗死预后的影响因素为治疗前CSS评分及治疗前NIHSS 评分。 |
| 英文摘要: |
| ABSTRACT Objective: This study was to investigate the influence factors of different doses of agatroban combined with butylphthalein on the effect and prognosis of patients with acute cerebral infarction. Methods: A total of 90 cases of emergency acute cerebral infarction admitted to our hospital from June 2019 to August 2022 were studied, and they were divided into a high-dose group (receiving high-dose agattriban combined with butylphthalide) and a low-dose group (receiving low-dose agattriban combined with butylphthalide) with 45 cases in each group by random number table method. The clinical efficacy and prognosis of the two groups after 7 days of treatment were compared, and the neurological function [Chinese Stroke Scale (CSS) score and neurological function (NIHSS) score] of the two groups were analyzed before treatment and after 7 days of treatment. Patients were divided into good prognosis group and poor prognosis group according to different prognosis. Single/multifactor Logisitic regression was used to analyze the prognostic factors of acute cerebral infarction. Results: (1) The clinical efficacy of the two groups was included in the study and the difference between the groups was compared. The results showed that the total effective rate of the high-dose group was higher than that of the low-dose group (P<0.05). (2) The neurological function of the two groups was evaluated by CSS score and NIHSS score, and the difference between the two groups was compared. The results showed that before treatment, CSS score and NIHSS score were compared between the two groups (P>0.05). After 7 days of treatment, the CSS score and NIHSS score in the high-dose group were higher than those in the low-dose group (P<0.05). (3) The prognosis of the two groups was included in the study using mRS Score assessment and the difference between the groups was compared. The results showed that the good prognosis of the high-dose group was 2.22% (1/45) higher than that of the low-dose group, 15.56% (7/45) (P<0.05). (4) Age of patients with good prognosis, pre-treatment CSS score and pre-treatment NIHSS score were different from the poor prognosis group (P<0.05). (5) With the prognosis of acute cerebral infarction as the dependent variable and the indicators with differences in the single factor as the independent variable, the factors affecting the prognosis of acute cerebral infarction were CSS score before treatment and NIHSS score before treatment by multifactor Logisitic regression analysis. Conclusion: High-dose agatroban combined with butylphthalide can effectively treat patients with acute cerebral infarction, and the prognostic factors of acute cerebral infarction are CSS score before treatment and NIHSS score before treatment. |
|
View Full Text
View/Add Comment Download reader |
| Close |
